Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $27.1111.

A number of brokerages have recently commented on NTLA. Canaccord Genuity Group dropped their price target on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, June 3rd. Wedbush reaffirmed a “neutral” rating and set a $7.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 16th. Wall Street Zen raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 6th. Royal Bank Of Canada dropped their price target on Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Finally, Chardan Capital dropped their price target on Intellia Therapeutics from $68.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, August 11th.

Intellia Therapeutics Trading Up 1.2%

NTLA stock opened at $11.42 on Friday. The stock’s fifty day simple moving average is $11.61 and its two-hundred day simple moving average is $9.61. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $23.76. The stock has a market cap of $1.23 billion, a P/E ratio of -2.43 and a beta of 2.28.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million for the quarter, compared to analysts’ expectations of $12.26 million. During the same quarter in the previous year, the firm earned ($1.52) earnings per share. The business’s revenue was up 104.3% on a year-over-year basis. As a group, analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Edward J. Dulac III sold 7,462 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares in the company, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William J. Chase acquired 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were bought at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares in the company, valued at $1,350,970.79. This trade represents a 288.24% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 12,534 shares of company stock worth $153,837 in the last ninety days. Insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in NTLA. Northern Trust Corp raised its stake in shares of Intellia Therapeutics by 13.0% during the 4th quarter. Northern Trust Corp now owns 979,137 shares of the company’s stock valued at $11,417,000 after purchasing an additional 112,847 shares during the period. Deutsche Bank AG raised its stake in shares of Intellia Therapeutics by 12.1% during the 4th quarter. Deutsche Bank AG now owns 252,501 shares of the company’s stock valued at $2,944,000 after purchasing an additional 27,282 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after purchasing an additional 1,100 shares during the period. Lazard Asset Management LLC raised its stake in shares of Intellia Therapeutics by 7.3% during the 4th quarter. Lazard Asset Management LLC now owns 109,500 shares of the company’s stock valued at $1,276,000 after purchasing an additional 7,488 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Intellia Therapeutics by 7.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 227,255 shares of the company’s stock worth $2,647,000 after acquiring an additional 15,888 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.